Lung Cancer

Lung cancer is the leading cause of cancer deaths in women and men both in the United States and throughout the world. Lung cancer has surpassed breast cancer as the leading cause of cancer deaths in women. In the United States alone over 159,000 people are projected to die from lung cancer in 2010, which is more than the number of deaths from colon and rectal, breast and prostate cancer combined.

According to the National Cancer Institute, 86% of all people diagnosed with lung cancer die within 5 years with only about 2% surving if diagnosed with lung cancer that has spread to other areas of the body.

However, the survival rates for lung cancers diagnosed at the earliest stage are higher with 49% surviving for five years or longer. Early detection is the key to survivability for most cancers but even more so for lung cancer due to the large number of individuals and families impacted by this devastating disease.

Provista has developed a simple blood test for the early detection of lung cancer called the "LC Sentinel™ Test. Early clinical performance data on LC Sentienl has demonstrated a sensitivity of 87%, specificity of 95% and an ROC accuracy of 0.97 for the detection of lung cancer in a combined study of men and women.

This test will be released to the general public in the next few months as a CLIA Laboratory Developed Test (LDT). For individuals and practitioners interested in finding out more details about LC Sentinel and its date of availablity, please contact Provista's Customer Service Department.

Call 602-224-5500, or by E-mail at Answers@ProvistaDX.com to be put on the Company's mailing list for diagnostic updates.